Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Methods and Composition for Live Bubonic Plague Vaccine Based on Yersinia Pestis * * * Gene Deletion, 57460 [E9-26790]
Download as PDF
57460
Federal Register / Vol. 74, No. 214 / Friday, November 6, 2009 / Notices
Annual Burden Hours: 4,100.
Needs and Uses: The information
collection requirement is necessary to
obtain data on candidate’s background
and aptitude in determining eligibility
and selection to the Air Force Academy.
Affected Public: Individuals or
households.
Frequency: On occasion.
Respondent’s Obligation: Required to
obtain or retain benefits.
OMB Desk Officer: Ms. Jasmeet
Seehra.
Written comments and
recommendations on the proposed
information collection should be sent to
Ms. Seehra at the Office of Management
and Budget, Desk Officer for DoD, Room
10236, New Executive Office Building,
Washington, DC 20503.
You may also submit comments,
identified by docket number and title,
by the following method:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Instructions: All submissions received
must include the agency name, docket
number and title for this Federal
Register document. The general policy
for comments and other submissions
from members of the public is to make
these submissions available for public
viewing on the Internet at https://
www.regulations.gov as they are
received without change, including any
personal identifiers or contact
information.
DOD Clearance Officer: Ms. Patricia
Toppings.
Written requests for copies of the
information collection proposal should
be sent to Ms. Toppings at WHS/ESD/
Information Management Division, 1777
North Kent Street, RPN, Suite 11000,
Arlington, VA 22209–2133.
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
252,675 entitled ‘‘Enhanced Substrates
for the Protease Activity of Serotype a
Botulinum Neurotoxin,’’ filed October
18, 2009. The United States
Government, as represented by the
Secretary of the Army, has rights to this
invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Assessment,
(301) 619–6664, both at telefax (301)
619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to the use of enhanced
substrates for the protease activity of
serotype A botulinum neurotoxin.
Dated: October 26, 2009.
Patricia L. Toppings,
OSD Federal Register Liaison Officer,
Department of Defense.
[FR Doc. E9–26706 Filed 11–5–09; 8:45 am]
ACTION:
BILLING CODE 5001–06–P
DEPARTMENT OF DEFENSE
mstockstill on DSKH9S0YB1PROD with NOTICES6
Department of the Army
Availability for Non-Exclusive,
Exclusive, or Partially Exclusive
Licensing of U.S. Provisional Patent
Application Concerning Enhanced
Substrates for the Protease Activity of
Serotype a Botulinum Neurotoxin
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
SUMMARY: Announcement is made of the
availability for licensing of the
VerDate Nov<24>2008
18:23 Nov 05, 2009
Jkt 220001
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9–26787 Filed 11–5–09; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive,
Exclusive, or Partially Exclusive
Licensing of U.S. Provisional Patent
Application Concerning Methods and
Composition for Live Bubonic Plague
Vaccine Based on Yersinia Pestis * * *
Gene Deletion
Department of the Army, DoD.
Notice.
AGENCY:
SUMMARY: Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
242,113 entitled ‘‘Methods and
Composition for Live Bubonic Plague
Vaccine Based On Yersinia Pestis * * *
Gene Deletion,’’ filed September 14,
2009. The United States Government, as
represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
PO 00000
Frm 00014
Fmt 4703
Sfmt 4703
Research and Technology Assessment,
(301) 619–6664, both at telefax (301)
619–5034.
The
invention relates to the creation of live
vaccines by removing a specific gene,
which is essential for virulence (the
ability of a pathogen to make sick or kill
a human or an animal) from a pathogen.
SUPPLEMENTARY INFORMATION:
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9–26790 Filed 11–5–09; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army; Corps of
Engineers
Inland Waterways Users Board
AGENCY: Department of the Army, U.S.
Army Corps of Engineers, DoD.
ACTION:
Notice of open meeting.
SUMMARY: In accordance with 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), announcement is
made of the forthcoming meeting.
Name of Committee: Inland Waterways
Users Board (Board).
Dates: December 15, 2009.
Location: The Westin New Orleans Canal
Place, 100 Rue Iberville, New Orleans,
Louisiana 70130 (504–566–7006 or 1–888–
627–8180).
Time: Registration will begin at 8 a.m. and
the meeting is scheduled to adjourn at
approximately 1 p.m.
Agenda: The Board will hear the results of
the Inland Marine Transportation System
(IMTS) Investment Strategy Team activities,
as well as the status of the funding for inland
navigation projects and studies and the status
of the Inland Waterways Trust Fund.
FOR FURTHER INFORMATION CONTACT: Mr.
Mark R. Pointon, Headquarters, U.S.
Army Corps of Engineers, CECW–ID,
441 G Street, NW., Washington, DC
20314–1000; Ph: 202–761–4691.
The
meeting is open to the public. Any
interested person may attend, appear
before, or file statements with the
committee at the time and in the
manner permitted by the committee.
SUPPLEMENTARY INFORMATION:
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9–26786 Filed 11–5–09; 8:45 am]
BILLING CODE 3720–58–P
E:\FR\FM\06NON1.SGM
06NON1
Agencies
[Federal Register Volume 74, Number 214 (Friday, November 6, 2009)]
[Notices]
[Page 57460]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26790]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Provisional Patent Application Concerning Methods and
Composition for Live Bubonic Plague Vaccine Based on Yersinia Pestis *
* * Gene Deletion
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Announcement is made of the availability for licensing of the
invention set forth in U.S. Provisional Patent Application Serial No.
61/242,113 entitled ``Methods and Composition for Live Bubonic Plague
Vaccine Based On Yersinia Pestis * * * Gene Deletion,'' filed September
14, 2009. The United States Government, as represented by the Secretary
of the Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research and Technology Assessment, (301) 619-6664,
both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION: The invention relates to the creation of
live vaccines by removing a specific gene, which is essential for
virulence (the ability of a pathogen to make sick or kill a human or an
animal) from a pathogen.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-26790 Filed 11-5-09; 8:45 am]
BILLING CODE 3710-08-P